Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.97 USD | -7.44% | -12.83% | -32.78% |
13/05 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
08/05 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.78% | 217M | |
+7.57% | 223B | |
+11.35% | 195B | |
+18.57% | 144B | |
+29.85% | 111B | |
+2.32% | 65.19B | |
+13.75% | 53.02B | |
+2.68% | 50.28B | |
+6.80% | 44.15B | |
+1.89% | 36.45B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating